SymBio Pharmaceuticals Limited [4582.T]
TOKYO, Apr 01 (Pulse News Wire) – SymBio Pharmaceuticals Limited (4582.T) reported the monthly exercise status of its 58th and 66th warrants for March 2026. The 58th warrant was issued to CVI Investments, Inc.
On June 01, 2022, while the 66th warrant was issued to EVO FUND on August 12, 2025. Both warrants had no exercises during the month of March. For the 58th warrant, due to changes in regulations, detailed monthly exercise reports are now required. However, the 67th warrant issued to EVO FUND on August 12, 2025, has a contractual restriction preventing its exercise until August 13, 2027, thus no report was provided for this warrant.
As of the end of March, there were 20,000 outstanding warrants for the 58th issue out of a total issuance of 20,000 units, representing a ratio of 0%. The 66th warrant had no outstanding units remaining, with a total issuance of 200,000 units, indicating a ratio of 0%. Detailed exercise prices and conditions for the 66th and 58th warrants remained consistent throughout March, with exercise prices ranging from 114 to ¥162 per share. No shares were delivered or transferred during the reporting period.
Further details on these warrants can be found in previous announcements dated May 16, 2022, and July 22, 2025.
🟢 Confidence: High AI-translated content.